These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 30406049)

  • 1. Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles.
    Furfaro LL; Payne MS; Chang BJ
    Front Cell Infect Microbiol; 2018; 8():376. PubMed ID: 30406049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phage Therapy in the Twenty-First Century: Facing the Decline of the Antibiotic Era; Is It Finally Time for the Age of the Phage?
    Hesse S; Adhya S
    Annu Rev Microbiol; 2019 Sep; 73():155-174. PubMed ID: 31185183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivering phage therapy per os: benefits and barriers.
    Zelasko S; Gorski A; Dabrowska K
    Expert Rev Anti Infect Ther; 2017 Feb; 15(2):167-179. PubMed ID: 27885865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ameliorating the antimicrobial resistance crisis: phage therapy.
    Saha D; Mukherjee R
    IUBMB Life; 2019 Jul; 71(7):781-790. PubMed ID: 30674079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy.
    Malik DJ; Sokolov IJ; Vinner GK; Mancuso F; Cinquerrui S; Vladisavljevic GT; Clokie MRJ; Garton NJ; Stapley AGF; Kirpichnikova A
    Adv Colloid Interface Sci; 2017 Nov; 249():100-133. PubMed ID: 28688779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
    Luong T; Salabarria AC; Roach DR
    Clin Ther; 2020 Sep; 42(9):1659-1680. PubMed ID: 32883528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections.
    Siopi M; Skliros D; Paranos P; Koumasi N; Flemetakis E; Pournaras S; Meletiadis J
    Clin Microbiol Rev; 2024 Sep; 37(3):e0004424. PubMed ID: 39072666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phages & antibiotic resistance: are the most abundant entities on earth ready for a comeback?
    Hill C; Mills S; Ross RP
    Future Microbiol; 2018 May; 13():711-726. PubMed ID: 29792526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards Inhaled Phage Therapy in Western Europe.
    Wienhold SM; Lienau J; Witzenrath M
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30909579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages.
    Cisek AA; Dąbrowska I; Gregorczyk KP; Wyżewski Z
    Curr Microbiol; 2017 Feb; 74(2):277-283. PubMed ID: 27896482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacteriophages: A Therapy Concept against Multi-Drug-Resistant Bacteria.
    Rohde C; Wittmann J; Kutter E
    Surg Infect (Larchmt); 2018; 19(8):737-744. PubMed ID: 30256176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal Models to Translate Phage Therapy to Human Medicine.
    Brix A; Cafora M; Aureli M; Pistocchi A
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phage Therapy in the Postantibiotic Era.
    Gordillo Altamirano FL; Barr JJ
    Clin Microbiol Rev; 2019 Apr; 32(2):. PubMed ID: 30651225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolutionary Rationale for Phages as Complements of Antibiotics.
    Torres-Barceló C; Hochberg ME
    Trends Microbiol; 2016 Apr; 24(4):249-256. PubMed ID: 26786863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Bacteriophage Therapy in Field Conditions and Possible Future Applications.
    Adhikari N; Acharya KP
    Curr Pharm Biotechnol; 2020; 21(5):364-373. PubMed ID: 31845630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic potential of bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model.
    Manohar P; Nachimuthu R; Lopes BS
    BMC Microbiol; 2018 Aug; 18(1):97. PubMed ID: 30170558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of clinical trials for phage therapy.
    Uchechukwu CF; Shonekan A
    J Med Microbiol; 2024 Sep; 73(9):. PubMed ID: 39320361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases.
    Matsuzaki S; Rashel M; Uchiyama J; Sakurai S; Ujihara T; Kuroda M; Ikeuchi M; Tani T; Fujieda M; Wakiguchi H; Imai S
    J Infect Chemother; 2005 Oct; 11(5):211-9. PubMed ID: 16258815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phage Therapy as a Protective Tool Against Pathogenic Bacteria: How Far We Are?
    Singh K; Biswas A; Chakrabarti AK; Dutta S
    Curr Pharm Biotechnol; 2023; 24(10):1277-1290. PubMed ID: 36503459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.